Diabetes Care
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hollander, P.
Right arrow Articles by Coniff, R. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hollander, P.
Right arrow Articles by Coniff, R. F.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Diabetes Care, Vol 20, Issue 3 248-253, Copyright © 1997 by American Diabetes Association

ARTICLES

Acarbose in the treatment of type I diabetes

P Hollander, X Pi-Sunyer and RF Coniff
International Diabetes Center, Park Nicollet Clinic, St. Louis Park, Minnesota, USA.

OBJECTIVE: This 36-week multicenter double-blind placebo-controlled study was designed to assess the safety and efficacy of acarbose, administered in conjunction with diet and insulin therapy, for the treatment of patients with type I diabetes. RESEARCH DESIGN AND METHODS: Acarbose was administered using a forced titration protocol in dosages ranging from 50 to 300 mg t.i.d. RESULTS: Treatment with acarbose was associated with a mean reduction in postprandial glucose levels (60 min after the administration of a test meal) of 59 mg/dl and a mean reduction in HbA1c levels of 0.48%. There was no difference in the incidence of hypoglycemia between treatment groups. Gastrointestinal events, including flatulence, diarrhea, and abdominal pain, were reported more frequently in acarbose-treated patients than in placebo-treated patients. CONCLUSIONS: Acarbose was found to be a safe and effective agent, when used in combination with diet and insulin therapy, for the treatment of type I diabetes.
Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Diabetes Spectr.Home page
P. Hollander
Anti-Diabetes and Anti-Obesity Medications: Effects on Weight in People With Diabetes
Diabetes Spectr, July 1, 2007; 20(3): 159 - 165.
[Abstract] [Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
H. A. Spiller and T. S. Sawyer
Toxicology of oral antidiabetic medications
Am. J. Health Syst. Pharm., May 15, 2006; 63(10): 929 - 938.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
S.-H. Hsiao, L.-H. Liao, P.-N. Cheng, and T.-J. Wu
Hepatotoxicity Associated with Acarbose Therapy
Ann. Pharmacother., January 1, 2006; 40(1): 151 - 154.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
L. Meyer, P. Bohme, I. Delbachian, P. Lehert, N. Cugnardey, P. Drouin, and B. Guerci
The Benefits of Metformin Therapy During Continuous Subcutaneous Insulin Infusion Treatment of Type 1 Diabetic Patients
Diabetes Care, December 1, 2002; 25(12): 2153 - 2158.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 1997 by the American Diabetes Association.